Back to Market返回行情

CERT Certara, Inc.

USHealthcare
$6.77-0.29%ClosedMarket Cap: $1.05B

As of 2026-07-10 16:00

Why CERT matters now

Certara, Inc. (CERT) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.77 with -0.29% on the session and $1.05B in market capitalization; recent performance reads 1-month +20.70% and YTD -37.12%.

The latest financial table shown here is Q1 2026, with revenue of $106.9M, net income of $-8.8M, and EPS of $-0.06. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 10.3%.

The latest indexable market news headline is "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT" from PRNewsWire.

Additional event context on this page matters because analyst consensus is Hold with a median target of $9.00; recent insider activity includes Corcoran Daniel filing M-Exempt. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

0.86

P/S

2.05

EV/EBITDA

10.00

DCF Value

$6.17

FCF Yield

10.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

58.1%

Operating Margin

4.1%

Net Margin

-3.6%

ROE

-1.4%

ROA

-1.0%

ROIC

1.3%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$106.9M$-8.8M$-0.06
Q4 2025$103.6M$-5.9M$-0.04
FY 2025$418.8M$-1.6M$-0.01
Q3 2025$104.6M$1.5M$0.01

Analyst Ratings

Consensus

Hold

Target (Consensus)

$9.00

Target (Median)

$9.00

Target Range

$8.00 - $10.00

Strong Buy: 0Buy: 5Hold: 7Sell: 0Strong Sell: 0
BMO CapitalMarket Perform
2026-05-12
Morgan StanleyEqual Weight
2026-05-12
Craig-HallumHold
2026-05-12
BairdNeutral
2026-05-12
BarclaysEqual Weight
2026-05-12

Trading Activity

Insider Trades

Corcoran Danielofficer: SVP and General Counsel
Sell2026-06-02
Corcoran Danielofficer: SVP and General Counsel
Sell2026-06-02
Corcoran Danielofficer: SVP and General Counsel
Sell2026-06-02
Corcoran Danielofficer: SVP and General Counsel
Sell2026-06-02
Corcoran Danielofficer: SVP and General Counsel
Sell2026-06-02

Company Info

Sector

Healthcare

Industry

Medical - Healthcare Information Services

Country

US

Exchange

Beta

1.49

Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and preclinical research to clinical trials, regulatory submissions, and market entry, the company's core mission is to accelerate the delivery of new medicines to patients by transforming these processes with its innovative biosimulation software and expertise. Its extensive portfolio of technology-enabled services includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, specialized regulatory writing and medical communications, regulatory operations support, and market access consultation. Furthermore, Certara offers a robust suite of software platforms covering mechanistic and empirical PK/PD biosimulation, data standardization and compliance, scientific informatics, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions, and market access communication. The company's clientele primarily comprises biopharmaceutical firms, academic institutions, and governmental organizations. Established in 2008 and headquartered in Princeton, New Jersey, Certara maintains a significant global presence, with operations spanning numerous countries including the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China.